SAN ANTONIO, June 2 (Reuter) - Immunomedics Inc said Monday
it had favorable clinical results in studies of three of its
diagnostic imaging products CEA-Scan for breast cancer,
AFP-Scan for hepatocellular cancer and LeukoScan for acute,
atypical appendicitis.
In a study of 41 women with non-palpable, indeterminate
mammograms, where actual presence of disease was confirmed in
only five, or 12 percent, of the cases, CEA-Scan demonstrated a
sensitivity of 60 percent and specificity of 92 percent, it
said.
In the second study, AFP-Scan achieved a higher sensitivity
and specificity than computed tomography, with an overall
accuracy of 88 percent versus 52 percent, the company said.
In the third study, the company reported on the ability of
LeukoScan to detect or rule out acute, non-classic
appendicitis.
The agent was studied in 94 patients with a suspicion of
the disease, the company said.
In 21 surgical patients, LeukoScan was positive for 19, and
was negative in 62 out of 73 surgical and non-surgical patients
who did not have appendicitis, the company said. |
